Allogene Therapeutics, Inc.
Allogene Therapeutics is a clinical-stage immuno-oncology company developing genetically engineered allogeneic T cell product candidates for cancer and autoimmune diseases. Its off-the-shelf approach uses T cells from healthy donors, engineered to target cancer cells or pathogenic autoreactive cells. The company’s three core programs are cema-cel, which targets CD19 and is being developed for large B-cell lymphoma; ALLO-316, which targets CD70 and is being developed for renal cell carcinoma; and ALLO-329, which targets CD19 and CD70 and is being developed for systemic lupus erythematosus, idiopathic inflammatory myopathies, and systemic sclerosis. Its pipeline also includes other candidates, though development priorities focus on these three programs. Allogene Therapeutics develops its candidates for clinical studies and manufactures them at its cGMP facility, Cell Forge 1, in Newark, California. The company holds commercial rights to cema-cel and certain additional candidates in the United States, the European Union, and the United Kingdom. Its headquarters are in South San Francisco, California.
Allogene Therapeutics (ALLO) will report Q3 2026 results on November 5, followed by a conference call. On November 9, it will present preliminary safety and efficacy data from its Phase 1 RESOLUTION study of ALLO-329, an investigational CAR T therapy for autoimmune diseases, at the ACR Convergence meeting. The company develops allogeneic CAR T cell products for cancer and autoimmune diseases.
Latigo Biotherapeutics and Eikon Therapeutics appointed new executives following their IPOs. Allogene Therapeutics and LB Pharma also announced leadership changes, reflecting broader biotech sector restructuring. These moves are part of organizational development in the public market.
Allogene Therapeutics, Inc. (ALLO) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (b) On August 31, 2026, Geoffrey Parker, the Executive Vice President and Chief Financial Officer and principal financial o
Over the past 7 days, AlphAI's AI scored 1 news story mentioning ALLO (Allogene Therapeutics, Inc.). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.
Recent ALLO coverage spans earnings, financial news and corporate actions.
In the last 30 days, ALLO insiders filed 1 SEC Form 4 transaction — no purchases and 1 sale ($49K). The most active reporter was Parker Geoffrey M., CHIEF FINANCIAL OFFICER, with 1 filing.
The upcoming earnings release and early‑stage data presentation are likely to drive short‑term volatility.
Management turnover may create short‑term uncertainty.
Executive departure may affect financial oversight and investor confidence.
The earnings release shows sizable cash reserves but ongoing losses, indicating near‑term financing stability but reliance on upcoming trial data.
Beat on narrower loss plus higher liquidity and ongoing ALPHA3 progress should support near-term sentiment, but it is not a fundamental re-rate without new efficacy readout.
AlphAI scores every news story that mentions ALLO with an AI model for sentiment and relevance, and aggregates insider trades from Allogene Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Allogene Therapeutics (ALLO) will report Q3 2026 results on November 5, followed by a conference call. On November 9, it will present preliminary safety and efficacy data from its Phase 1 RESOLUTION study of ALLO-329, an investigational CAR T therapy for autoimmune diseases, at the ACR Convergence meeting. The company develops allogeneic CAR T cell products for cancer and autoimmune diseases.
1 min readLatigo Biotherapeutics and Eikon Therapeutics appointed new executives following their IPOs. Allogene Therapeutics and LB Pharma also announced leadership changes, reflecting broader biotech sector restructuring. These moves are part of organizational development in the public market.
2 min readAllogene Therapeutics, Inc. (ALLO) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (b) On August 31, 2026, Geoffrey Parker, the Executive Vice President and Chief Financial Officer and principal financial o
1 min readAllogene (ALLO) reported a Q2 2026 net loss of $42.7M, or $0.13 per share, with $4.6M in collaboration revenue. Cash reserves totaled $423.6M, providing a runway into 2029. Key clinical updates include 58.3% MRD negativity in the ALPHA3 trial and a 31% ORR for ALLO-316. The company aims to expand access to CAR T therapies in community settings. FDA granted RMAT and Fast Track designations for cema-cel. Management highlighted upcoming milestones and risks, including small data sets and safety cha
2 min readAllogene Therapeutics (ALLO) reported Q2 2026 EPS loss of 13 cents, narrower than the Zacks Consensus loss of 16 cents, helped by lower R&D costs. Collaboration revenue from related parties was $4.6 million. Cash, cash equivalents and investments rose to $423.6 million after a $200.4 million April offering. The company reiterated 2026 operating expense guidance and expects ALPHA3 interim EFS data in mid-2027.
6 min readAllogene Therapeutics, Inc. (ALLO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Allogene Therapeutics Reports Second Quarter 2026 Financial Results and Business Update • Pivotal Phase 2 ALPHA3 Program in 1L Large B-cell Lymphoma (LBCL): ◦ Recent Interim Futility Analysis Supports Cemacabtagene Ansegedleucel’s (Cema-Cel) Potential as an Outpatien
6 min readDelveInsight forecasts the CAR T-cell therapy market for non-Hodgkin lymphoma will grow at about 7% CAGR through 2036, driven by rising relapsed/refractory incidence and broader clinical adoption. It cites pipeline and trial activity for products including Miltenyi’s Zamtocabtagene, Novartis’ Rapcabtagene, Allogene’s Cemacabtagene, and others. Recent updates include FDA approvals for TECARTUS and label changes for YESCARTA, plus early LB2501 results from Legend Biotech.
7 min readAllogene Therapeutics, Inc. (ALLO) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. allo-20260618 0001737287 FALSE 0001737287 2026-06-18 2026-06-18 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ____________________ FORM 8-K ____________________ CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of
4 min readAllogene Therapeutics (ALLO) stock slumped by 16.01% after announcing a $175M underwritten public offering of 87.5 million shares at $2.00 per share, significantly diluting existing shareholders. The offering, designed to fund clinical trials and R&D for its CAR-T pipeline, led to an 18% intraday price drop on increased volume. Traders are closely monitoring ALLO due to the dilution, insider selling intentions, and its high-burn, high-volatility biotech profile.
4 min read
